GM-CSF/mavrilimumab in GCA masterclass from Maria Cid this morning. Sadly, as John Stone & Sharon Chung ask and Maria Cid reflects on, we're not sure what happens next, despite the promising phase 2 & elegant MOA. No current plans for a mavrilimumab GCA phase 3 #ACR22 @RheumNow https://t.co/c5PSqnFnC2